Delivery of lysosomal enzymes for therapeutic use: Glucocerebrosidase as an example

Expert Opinion on Drug Delivery

Volumn 3, Issue 6, 2006, Pages 771-782

  Grabowski, Gregory A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Enzyme replacement therapy; Gaucher disease; Inborn errors of metabolism; Lipidosis; Sphingolipidosis

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALGLUCERASE; ALGLUCOSIDASE ALPHA; ANTIHISTAMINIC AGENT; CHAPERONE; COMPLEMENTARY DNA; CORTICOSTEROID; GLUCOSIDASE; GLUCOSYLCERAMIDASE; IMIGLUCERASE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; KIFUNENSINE; LARONIDASE; LIPID; LYSOSOME ENZYME; MANNOSE RECEPTOR; MANNOSIDASE 1 INHIBITOR; MANNOSIDASE INHIBITOR; OLIGOSACCHARIDE; SAPONIN; SAPONIN C; TETRACYCLINE; UNCLASSIFIED DRUG;

ANEMIA; ANTIBODY PRODUCTION; BONE DISEASE; BONE MARROW TRANSPLANTATION; CELL BASED GENE THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; COST EFFECTIVENESS ANALYSIS; CRYSTAL STRUCTURE; DOSE LIVER FUNCTION RELATION; DRUG ANTIGENICITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SCREENING; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME ENGINEERING; ENZYME MODIFICATION; ENZYME REGULATION; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GENE EXPRESSION SYSTEM; GLYCOGEN STORAGE DISEASE TYPE 2; HEART PALPITATION; HEPATOMEGALY; HUMAN; LUNG DISEASE; LYSOSOME STORAGE DISEASE; MACROPHAGE FUNCTION; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PARVOVIRUS VECTOR; PRURITUS; QUALITY OF LIFE; RETROVIRUS VECTOR; REVIEW; SPLENOMEGALY; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; URTICARIA; VIRAL GENE THERAPY; VOMITING;

ANIMALS; DRUG DELIVERY SYSTEMS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; LYSOSOMAL STORAGE DISEASES; RECOMBINANT PROTEINS;

EID: 33751206186     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.6.771     Document Type: Review

References (87)

1. BEUTLER E, GRABOWSKI GA: Gaucher disease. In: The Metabolic and Molecular Bases of Inherited Diseases. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, NY, USA (2001):3635-3668.
2. HARMATZ P, WHITLEY CB, WABER L et al.: Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr. (2004) 144:574-580.
3. KAKKIS ED, MUENZER J, TILLER GE et al.: Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J Med. (2001) 344:182-188.
4. ENG CM, GUFFON N, WILCOX WR et al.: Safety and efficacy of recombinant human a-galactosidase α-replacement therapy in Fabry's disease. N. Eng. J. Med. (2001) 345:9-16.
5. AMALFITANO A, BENGUR AR, MORSE RP et al.: Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a Phase I/II clinical trial. Genet. Med. (2001) 3:132-138.
6. SIRRS S, IRVING J, MCCAULEY G et al. Failure of resting echocardiography and cardiac catheterization to identify pulmonary hypertension in two patients with type I Gaucher disease. J Inherit. Metab. Dis. (2002) 25:131-132.
7. KATTLOVE HE, WILLIAMS JC, GAYNOR E, SPIVACK M, BRADLEY RM, BRADY RO: Gaucher cells in chronic myelocyric leukemia: an acquired abnormality. Blood (1969) 33:379-390.
8. LEE RE: The fine structure of the cerebroside occurring in Gaucher's disease. Proc. Natl. Acad. Sci. USA (1968) 61:484-489.
9. BOVEN LA, VAN MEURS M, BOOT RG et al.: Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. (2004) 122:359-369.
10. DEDUVE C: Lysosomes revisited. Eur. J. Biochem. (1983) 137:391.
11. LEINEKUGEL P, MICHEL S, CONZELMANN E, SANDHOFF K: Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum. Genet. (1992) 88:513-523.
12. CONZELMANN E, SANDHOFF K: Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev. Neurosci. (1983) 6:58-71.
13. FRATANTONI JC, HALL CW, NEUFELD EF: The defect in Hurler and Hunter syndromes II: deficiency of speicfic factors involved in mucopolysaccharide degradation. Proc. Natl. Acad. Sci. USA (1969) 64:360.
14. HOROWITZ M, WILDER S, HOROWITZ Z, REINER 0, GELBART T, BEUTLER E: The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics (1989) 4:87-96.
15. DOLL RF, BRUCE A, SMITH FI: Regulation of the human acid β-glucosidase promoter in multiple cell types. Biochim. Biophys. Acta (1995) 1261:57-67.
16. DOLL RF, SMITH FI: Regulation of expression of the gene encoding human acid β-glucosidase in different cell types. Gene (1993) 127:255-260.
17. XU YH, GRABOWSKI GA. Translation modulation of acid β-glucosidase in HepG2 cells: participation of the PKC pathway. Mol. Genet. Metab. (2005) 84:252-264.
18. XU YH, BUSALD C, GRABOWSKI GA. Reconstitution of TCP80/NF90 translation inhibition activity in insect cells. Mol. Genet. Metab. (2000) 70:106-115.
19. XU YH, GRABOWSKI GA: Translational inefficiency of acid β-glucosidase mRNA in transgenic mammalian cells. Mol. Genet. Metab. (1998) 64:87-98.
20. BERGMANN JE, GRABOWSKI GA: Posttranslational processing of human lysosomal acid β-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. Am. J. Hum. Genet. (1989) 44:741-750.
21. VAN WEELY S, AERTS JM, VAN LEEUWEN MB et al: Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase. Eur. J. Biochem. (1990) 191:669-677.
22. ERICKSON AH, GINNS EI. BARRANGER JA: Biosynthesis of the lysosomal enzyme glucocerebrosidase. J. Biol. Chem. (1985) 260:14319-14324.
23. RIJNBOUTT S, AERTS HM, GEUZE HJ, TAGER JM, STROUS GJ: Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells. J. Biol. Chem. (1991) 266:4862-4868.
24. AERTS JM, SCHRAM AW, STRIJLAND A et al.: Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. Biochim. Biophys. Acta (1988) 964:303-308.
25. LEONOVA T, GRABOWSKI CA: Fate and sorting of acid β-glucosidase in transgenic mammalian cells. Mol. Genet. Metab. (2000) 70:281-294.
26. AERTS JM, HEIKOOP J, VAN WEELY S et al.: Characterization of glucocerebrosidase in peripheral blood cells and cultured blastoid cells. Exp. Cell Res. (1988) 177:391-398.
27. TAKASAKI S, MURRAY GJ, FURBISH FS, BRADY RO, BARRANGERJA, KOBATA A: Structure of the N-asparagine-linked oligosaccharide units of human placental β-glucocerebrosidase. J. Biol. Chem. (1984) 259:10112-10117.
28. BERG-FUSSMAN A, GRACE ME, IOANNOU Y, GRABOWSKI GA: Human β-glucosidase: N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J. Biol Chem. (1993) 268:14861-14866.
29. GRACE ME, GRABOWSKI GA: Human acid β-glucosidase: glycosylation is required for catalytic activity. Biochem. Biophys. Res. Commun. (1990) 168:771-777.
30. WILEMAN TE, LENNARTZ MR, STAHL PD: Identification of the macrophage mannose receptor as a 175 kDa membrane protein. Proc. Natl. Acad. Sci. USA (1986) 83:2501-2505.
31. LENNARTZ MR, COLE FS, STAHL PD: Biosynthesis and processing of the mannose receptor in human macrophages. J. Biol. Chem. (1989) 264:2385-2390.
32. EZKOWITZ AB, SASTRY K, BAILLY P, WARNER A: Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J. Exp. Med. (1990) 172:1785-1794.
33. PONTOW SE, KERY V, STAHL PD: Mannose receptor. Int. Rev. Cytol. (1997) 137:221-244.
34. GRABOWSKI GA, GATT S, HOROWITZ M: Acid β-glucosidase: enzymology and molecular biology of Gaucher disease. Crit. Rev. Biochem. Mol. Biol. (1990) 25:385-414.
35. GRABOWSKI GA, HOROWITZ M: Caucher disease: molecular, genetics and enzymologic aspects, Bailliere's Clin. Hema. (1997) 10:635-656.
36. QI X, GRABOWSKI GA: Acid β-glucosidase: intrinsic fluorescence and conformational changes induced by phospholipids and saposin C. Biochemistry (1998) 37:11544-11554.
37. RORMAN EG, GRABOWSKI GA: Molecular cloning of a human co-β-glucosidase cDNA: evidence that four sphingolipid hydrolase activator proteins are encoded by single genes in humans and rats. Genomics (1989) 5:486-492.
38. O'BRIEN JS, KRETZ KA, DEWJI N, WENGER DA, ESCH F, FLUHARTY AL: Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science (1988) 241:1098-1101.
39. SANDHOFF K, KOLTER T, HARZER K: Sphingolipid Activator Proteins. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet A. Sly W, Valle D (Eds), McGraw-Hill, New York, NY, USA (2001):18.
40. WILKENING G, LINKE T, UHLHORN-DIERKS G, SANDHOFF K: Degradation of membrane-bound ganglioside GM1: stimulation by bis(monacylglycero)phosphate and the activator proteins sap-B and GM2-AP. J. Biol. Chem. (2000) 275:35814-35819.
41. CHRISTOMANOU H, CHABAS A, PAMPOLS T, GUARDIOLA A. Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder. Min. Wochenschr. (1989) 67:999-1003.
42. DVIR H, HAREL M, MCCARTHY AA et al.: X-ray structure of human acid-β-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. (2003) 4:704-709.
43. PREMKUMAR L, SAWKAR AR, BOLDIN-ADAMSKY S et al: X-ray structure of human acid β-glucosidase covalently-bound to conduritol B epoxide: Implications for Gaucher disease. J. Biol. Chem. (2005) 280:23815-23819.
44. LIOU B, KAZIMIERCZUK A, ZHANG M, SCOTT CR, HEGDE RS, GRABOWSKI GA: Analyses of variant acid β-glucosidases: effects of Gaucher disease mutations. J. Biol. Chem. (2006) 281:4242-4253.
45. MIAO S, MCCARTER J, TULL D et al.: Identification of Glu340 as the active site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry. J. Biol. Chem. (1994) 269:10975-10978.
46. OSIECKI-NEWMAN K, FABBRO D, LEGLER G, DESNICK RJ, GRABOWSKI GA. Human acid β-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites. Biochim. Biophys. Acta (1987) 915:87-100.
47. OSIECKI-NEWMAN K, LEGLER G, GRACE M et al: Human acid β-glucosidase: inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites. Enzyme (1988) 40:173-188.
48. TSUJI S, CHOUDARY PV, MARTIN BM, WINFIELD S, BARRANGER JA, GINNS EI: Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase. J. Biol. Chem. (1986) 261:50-53.
49. SORGE J, WEST C, WESTWOOD B, BEUTLER E: Molecular cloning and nucleotide sequence of the human glucocerebrosidase gene. Proc. Natl. Acad. Sci. USA (1985) 82:7289-7293.
50. GRACE ME, NEWMAN KM, SCHEINKER V, HE G-S, BERG-FUSSMAN A, GRABOWSKI GA. Analysis of human acid β-glucosidase by site-directed mutagenesis and heterologous expression. J. Biol, Chem. (1994) 269:2283-2291.
51. FRIEDMAN B, VADDI K, PRESTON C, MAHON E, CATALDO JR, MCPHERSON JM: A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived β-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood (1999) 93:2807-2816.
52. LEE SJ, EVERS S, ROEDER D et al: Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science (2002) 295:1898-1901.
53. BARTON NW, BRADY RO, DAMBROSIA JM et al: Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. (1991) 327:1464-1470.
54. WEINREB N, CHARROW J, ANDERSSON HC et al: Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of threatment: a report from the Gaucher registry. Am. J. Med. (2002) 113:112-119.
55. WEINREB NJ, AGGIO MC, ANDERSSON HC et al: Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin. Hematol. (2004) 41:15-22.
56. XU YH, QUINN B, WITTE D, GRABOWSKI GA: Viable mouse models of acid β-glucosidase deficiency: the defect in Gaucher disease. Am. J. Pathol. (2003) 163:2093-2101.
57. MURRAY GJ, JIN F-S: Immunoelectron microscopic localization of mannose-terminal glucocerebrosidase in lysosomes of rat liver Kupfler cells. J. Histochem. Cytochem. (1995) 43:149-158.
58. BIJSTERBOSCH MK, DONKER W, VAN DE BILT H, VAN WEELY S, VAN BERKEL TJ, AERTS JM: Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur. J. Biochem. (1996) 237:344-349.
59. XU YH, PONCE E, SUN Y et al.: Turnover and distribution of intravenously administered mannose-terminated human acid β-glucosidase in murine and human tissues. Pediatr. Res. (1996) 39:313-322.
60. DU H, LEVINE M, GANESA C, WITTE DP, COLE ES, GRABOWSKI GA: The role of mannosylated enzyme and the marmose receptor in enzyme replacement therapy. Am. J. Hum. Genet. (2005) 77:1061-1074.
61. LUDMAN MD, LIPTON J, SHADEV I et al.: Gaucher's disease: Bone marrow transplantation (BMT) in rapidly progressive disease - implications for genetic therapy. Am. J. Hum. Genet. (1988) 43:A60-A60.
62. MISTRY PK, WRAIGHT EP, COX TM: Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet (1996) 348:1555-1559.
63. PASTORES GM, SIBILLE, AR, GRABOWSKI GA: Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood (1993) 82:408-416.
64. ZIMRAN A, ELSTEIN D, KANNAI R et al.: Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype and clinical features on response to treatment. Am. J. Med. (1994) 97:3-13.
65. PASTORES GM, WEINREB NJ, AERTS H et al.: Therapeutic goals in the treatment of Gaucher disease. Semin Hematol (2004) 41:4-14.
66. GRABOWSKI GA, CHARROW J, HOLLAK CE et al.: Analysis of enzyme replacement therapy dose-response relationships in patients with type 1 Gaucher disease. Am. Soc. Hum. Genet. (YEAR?). Abstract.
67. MOSCICKI RA, KINGMA W: The safety of Ceredase therapy in Gaucher disease: adverse effects and immune response. Gaucher Clin. Perspect. (1994) 2:7-10.
68. ROSENBERG MK, FITZPATRICK MA, RICHARDS SM: Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood (1999) 93:2081-2088.
69. ZHAO H, BAILEY LA, ELSAS LJ II, GRINZAID KA, GRABOWSKI GA: Gaucher disease: in vivo evidence for allele dose leading to neuronopathic and nonneuronopathic phenotypes. Am. J. Med. Genet. (2003) 116:52-56.
70. GRABOWSKI GA, BARTON NW, PASTORES G et al: Enzyme therapy in Gaucher disease type 1: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. (1995) 122:33-39.
71. SCHIFFMANN R, KOPP JB, AUSTIN HA et al.: Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA (2001) 285:2743-2749.
72. VAN DEN HOUTJM RA, DE KLERK JB, ARTS WF, SMEITINK JA, VAN DER PLOEG AT: Enzyme therapy for pompe disease with recombinant human α-glucosidase from rabbit milk. J. Inherit. Metab. Dis. (2001) 24:266-274.
73. VAN DEN HOUT JM, REUSER AJ, VULTO AG, LOONEN MC, CROMME-DIJKHUIS A, VAN DER PLOEG AT: Recombinant human α-glucosidase from rabbit milk in Pompe disease. Lancet (2000) 356:397-398.
74. ZHAO H, BAILEY LA, GRABOWSKI GA. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol. Dis. (2003) 30:90-96.
75. BRADY RO MG, OLIVER KL, LEITMAN SF, SNELLER MC, FLEISHER TA, BARTON NW: Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics (1997) 100:E11.
76. STARER F, SARGENT JD, HOBBS JR: Regression of the radiological changes of Gaucher's disease following bone marrow transplantation. Br. J. Radiol. (1987) 60:1189-1195.
77. HOBBS JR, JONES KH, SHAW PJ, LINDSAY I, HANCOCK M: Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher's syndrome. Lancet (1987) 1:1111-1115.
78. RAPPEPORT JM, BARRANGER JA, GINNS EI: Bone marrow transplantation in Gaucher disease. Birth Defects (1986) 22:101-101.
79. SVENNERHOLM L, ERIKSON A, GROTH CG, RINGDEN O, MANSSON JE: Norrbottnian type of Gaucher disease - clinical, biochemical and molecular biology aspects: successful treatment with bone marrow transplantation. Devel. Neuroscience (1991) 13:345-351.
80. RINGDEN O, GROTH CG, ERIKSON A, GRANQVIST S, MANSSON JE, SPARRELID E: Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation (1995) 59:864-870.
81. CHAN KW, WONG LT, APPLEGARTH D, DAVIDSON AG: Bone marrow transplantation in Gaucher's disease: effect of mixed chimeric state. Bone Marrow Transplant. (1994) 14:327-330.
82. MCEACHERN KA, NIETUPSKI JB, CHUANG WL et al.: AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J. Gene Med. (2006) 8:719-729.
83. SORGE J, KUHL W, WEST C, BEUTLER E: Gaucher disease: retrovirus-mediated correction of the enzymatic defect in cultured cells. Cold Spring Harb. Symp. Quant. Biol. (1986) 51 (Pt 2):1041-1046.
84. CHOUDARY PV, BARRANGER JA, TSUJI S et al: Retrovirus-mediated transfer of the human glucocerebrosidase gene to Gaucher fibroblasts. Mol. Biol. Med. (1986) 3:293-299.
85. KOLTER T, WENDELER M: Chemical chaperones - a new concept in drug research. Chembiochem. (2003) 4:260-264.
86. SAWKAR AR, CHENG WC, BEUTLER E, WONG CH, BALCH WE, KELLY JW. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. USA (2002) 99:15428-15433.
87. SAWKAR AR, ADAMSKI-WERNER SL, CHENG WC et al.: Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. (2005) 12:1235-1244.